LoDoCo2: Low-Dose Colchicine in Coronary Disease Trial Discussion
Sorry, the video is currently unavailable.
Drs. Ron and Waksman and Aernoud Fiolet discuss the LoDoCo 2 trial, which was presented at the European Society of Cardiology 2020 virtual congress on Aug. 31, 2020. The study found that low-dose colchicine reduces the risk of cardiovascular events in patients with chronic coronary disease.